Expression of the Escherichia coli enzyme nitroreductase (NTR) in mammalian cells enables them to activate the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954), leading to interstrand DNA cross-linking and apoptosis in both proliferating and quiescent cells. In the work reported here, we used human hepatocellular carcinoma and squamous carcinoma cell lines constitutively expressing NTR to demonstrate that the ntr/CB1954 system results in potent, long-lasting antitumoral effects in mice. We also demonstrate that this enzyme/prodrug combination results in antitumoral effects in vivo when only a minority of tumor cells express the enzyme, using either cells constitutively expressing NTR or ntr gene delivery in situ. Cancer Gene Therapy (2000) 7, 721-731
T he effectiveness of cancer chemotherapy is presently limited by dose-limiting toxicity to healthy tissues. Gene-directed enzyme prodrug therapy (GDEPT) is a targeted chemotherapy strategy in which a gene encoding an enzyme capable of converting a prodrug into a potent cytotoxic agent is expressed in the tumor but not in normal tissue. The two most well-characterized enzyme/prodrug systems use herpes simplex virus thymidine kinase (tk) together with the antiviral agent ganciclovir (GCV) or a bacterial cytosine deaminase (cd) together with 5-fluorocytosine. [1] [2] [3] Although highly effective against rapidly growing tumor models, the clinical effectiveness of these anti-metabolite-generating systems is likely to be limited by their inability to kill nondividing cells, which typically make up the bulk of the tumor mass. 4, 5 More recently, enzyme/prodrug systems that generate alkylating agents have been developed. These have attracted strong interest, as alkylating drugs can eliminate both dividing and nondividing cells and can cause significant bystander cell killing. 6 -9 We are evaluating the combination of the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) and the Escherichia coli nitroreductase (NTR). CB1954 is a weak monofunctional alkylating agent that is converted by NTR into 2-and 4-hydroxylamino derivatives. Cellular thioesters such as acetyl coenzyme A subsequently convert the latter into a powerful bifunctional alkylating agent 10 that can kill both proliferating and nonproliferating cells. 11, 12 At the molecular level, this cell killing involves induction of interstrand DNA cross-links and apoptosis. 10, 12, 13 Tumor cell lines expressing NTR in vitro after stable transfection with the ntr gene are usually at least a hundred times more sensitive to CB1954 than untransfected cells. 14, 15 Furthermore, bystander cell killing has been clearly demonstrated for tumor cells in vitro. 14 -16 Expression of NTR restricted either to the thymus and spleen (using the CD2 locus control region) or to the mammary gland (using the ␤-lactoglobulin promoter) in transgenic mice has been used to investigate cell killing in vivo with the ntr/CB1954 system. 12, 13 Both studies demonstrated selective cell killing after CB1954 administration but gave little information regarding bystander killing effects in vivo.
In this paper, we report studies on the antitumoral efficacy of the ntr/CB1954 system in nude mice using human tumor xenografts. Tumors derived from hepatocellular carcinoma and squamous carcinoma of the head and neck were studied. These tumor types will be among the earliest clinical targets for the GDEPT system, because they are amenable to targeting ntr gene delivery by direct intratumoral (i.t.) injection. Our studies demonstrate that the system can cause a complete regression of NTR-expressing tumors. In addition, they demonstrate a potent in vivo bystander effect.
MATERIALS AND METHODS

Expression vectors
The ntr gene was amplified by 24 cycles of polymerase chain reaction with genomic DNA of E. coli B/r as template and the following primers containing NotI and HindIII sites for subsequent cloning into pCR3 (Invitrogen, Groningen, The Netherlands): 5Ј-GTAAGCTTGCCGCCAGCCATGGATATCA-TTTCT-3Ј and 3Ј-GTGCGGCCGCGAATTACACTTCGGT-TAA-5Ј. After confirmatory DNA sequencing, the gene was recloned as a NotI-HindIII fragment into pJG1. 13 The resultant plasmid, pTX0147, expresses NTR from the human cytomegalovirus (CMV) early promoter/enhancer and also carries the ␤-globin second intron and poly(A) sequences and a G418 selectable marker. The plasmid pTX0340 was derived from pTX0147 by subcloning the NTR expression cassette into pBluescript (Stratagene, Amsterdam, The Netherlands) as a BglII-XbaI fragment and recircularization of a 4-kb BspHI fragment from the resultant plasmid, pTX0160. The plasmid pTX0340 lacks a selectable marker and was generated and propagated in the repressor titration strain DH1LacKan. 17 The control plasmid pCMV-LacZ was obtained from Promega (Southhampton, UK).
Cell lines and culture conditions
HepG2 cells were obtained from the American Type Culture Collection (Manassas, Va) and maintained as recommended by the supplier. HNX 14C cells 18 were kindly provided by Professor H. Newell (Cancer Research Unit, University of Newcastle, Newcastle, UK) and maintained in RPMI 1640 medium (Life Technologies, Paisley, UK) supplemented with 10% fetal calf sera (Life Technologies), 100 U/mL penicillin, and 100 g/mL streptomycin. Cell cultures were incubated in a humidified atmosphere of 5% CO 2 /95% air at 37°C. All cultures were demonstrated to be free of Mycoplasma. HepG2 and HNX 14C cell lines stably expressing NTR were derived by electroporation with ScaIlinearized pTX0147, G418 selection, and endpoint dilution cloning. NTR-expressing lines were identified by indirect immunostaining using a sheep anti-NTR antiserum.
In vitro cytotoxicity assay CB1954 was dissolved in dimethylsulfoxide (DMSO) (Sigma, St Louis, Mo) at 20 mg/mL and further diluted in culture medium.
Exponentially growing cells were exposed for 4 hours to a range of concentrations of CB1954. Next, cells were detached by brief trypsinization immediately after exposure to CB1954 and a single-cell suspension (Ͼ95% single cells) prepared by quenching the trypsin with growth medium and trituration of cell clumps by prolonged pipetting. Equal numbers of cells were then seeded into 10-cm Petri dishes; after a grow-out period, macroscopic colonies were stained with Coomassie blue and counted.
Animal studies
Tumor xenografts were grown in male BALB/c nu/nu mice (Paterson Institute for Cancer Research colony, Manchester, UK). After tumor implantation, mice were maintained in microisolator cages equipped with filter tops. All mice were free of specific pathogens and were 8 -12 weeks of age at the commencement of experimental procedures. All husbandry and investigational procedures to be described were performed in accordance with Home Office regulations.
Xenotransplantation was performed under general anesthesia, which was induced by intraperitoneal (i.p.) injection of 0.2 mL of a mixture containing 1 mg/mL xylizine (Chanelle Animal Health, Liverpool, UK) and 10 mg/mL ketamine (Willows Francis Veterinary, Crawley, UK). Exponentially growing cells cultured in vitro were used as tumor inocula. Cells were cultured in T225 flasks, harvested by trypsinization and centrifugation for 5 minutes at 800 ϫ g, washed, and resuspended in sterile saline solution. Cell viability was estimated by trypan blue dye exclusion, and only single-cell suspensions of Ͼ90% viability were used. For studies on bystander cell killing, NTR-expressing cells and untransfected parental cells were mixed in different proportions before inoculation. Mice were injected subcutaneously (s.c.) in the flank (HepG2 ϭ 5 ϫ 10 6 ; HNX 14C ϭ 2 ϫ 10 6 ). Tumor size was measured daily using Vernier calipers and was expressed as a surface area determined by multiplying the longest diameter by the greatest perpendicular diameter (length ϫ width ϭ mm 2 ). In accordance with Home Office regulations, animals were sacrificed when the calculated surface area of the tumor xenograft reached 100 mm 2 or were sacrificed in response to a Ͼ15% loss in body weight or signs of imminent ulceration.
CB1954 was administered by i.p. injection without anesthesia. The drug was dissolved in DMSO (Sigma) to give a concentration of 20 mg/mL and was then further diluted 1/5 in sterile saline solution immediately before dosing to give a final concentration of 4 mg/mL. For i.t. injections of DNA, tumor-bearing mice were lightly anesthetized using a third of the dose described above. A U-100 insulin syringe (Terumo, Leuven, Belgium) fitted with a 27-gauge needle was used to directly inject 40 g of plasmid DNA in 20 L of saline three times at two hourly intervals at equidistant sites along the long tumor axis.
Histology and immunohistochemistry
Tumor xenografts were carefully excised after humane sacrifice, fixed in a 4% solution of formalin in phosphate-buffered saline for 24 hours, and processed for paraffin embedding and sectioning using standard protocols. Serial 3-m sections were cut and stained with hematoxylin and eosin (H&E). NTR-expressing cells were visualized by indirect immunoperoxidase staining using a sheep anti-NTR antiserum (Polyclonal Antibodies Ltd, Dyfed, UK) and a Vectastain Elite avidin-biotin-complex kit (Vector Laboratories, Peterborough, UK). Histological sections were examined using standard microscopic equipment.
Statistical analysis
Differences between mean values were analyzed by Student's t test and were considered statistically significant when P was Ͻ.05. Survival curves were compared for statistical differences using the log-rank test and judged significant when P was Ͻ.05.
RESULTS
Selective killing of NTR-expressing HepG2 and HNX 14C cell lines in vitro
Clonal cell lines constitutively expressing NTR were prepared as described in Materials and Methods. The cell lines HepG2/ntr 7 and HNX 14C/ntr 8 showed the highest level of stable NTR expression as judged by immunostaining and were chosen for further studies. The sensitivity of these lines to CB1954 was confirmed by clonogenic assay; this assay was expected to provide the most sensitive measure of cytotoxicity, because it determines the proportion of cells capable of continued division (Fig 1) . The concentration of CB1954 required to give a 50% reduction in viability (IC 50 ) was 0.1 M for the HepG2/ntr 7 line and 0.7 M for the HNX 14C/ntr 8 line. These IC 50 s are less than the serum concentration that is able to be achieved by systemic administration of CB1954 (our unpublished preclinical and clinical data).
Tumorigenicity of NTR-expressing cell lines and tumor histology S.c. inoculation of nude mice with untransfected HepG2 and HNX 14C cells led to the appearance of palpable tumors in Ͼ50% of the animals. However, HepG2 graft formation was consistently less efficient, required a larger cell inoculum, and displayed a longer latency period. Notably, however, was a difference in the degree of vascularization. Histological examination revealed that HepG2 tumors contained abundant sinusoid-like blood vessels, whereas HNX 14C grafts were poorly differentiated with no obvious blood supply. Consistent with this finding, the former contained no significant areas of necrosis, whereas the latter were extensively necrotic (Fig 2) . Importantly, from a technical stand- point, both NTR-expressing lines formed tumors with an efficiency that was similar to the respective parental cell lines, indicating that expression of NTR did not itself prevent tumor formation. Growth rates were also very similar. Of critical importance, NTR expression was well-maintained during tumor growth in vivo; immunostaining of sections of small tumors with an anti-NTR antiserum showed that most HepG2/ntr 7 and HNX 14C/ntr 8 tumors were composed essentially of 100% NTR-expressing cells (Fig 2, A2 and B2) . A minor proportion of tumors contained up to 25% of cells with no detectable NTR, indicating some instability.
Selective ablation of HNX 14C and HepG2 tumor xenografts expressing NTR Before beginning antitumoral efficacy studies with NTRexpressing tumor xenografts, the maximum well-tolerated dose of CB1954 was determined for the BALB/c nude mouse strain. As shown in Figure 3 , a total CB1954 dose of 100 mg/kg body weight, given i.p. in five daily administrations of 20 mg/kg, was well-tolerated, with the most notable consequence being temporary and minor body weight loss. In contrast, a 400-mg dose (5 ϫ 80 mg/kg) led to a severe and progressive loss of body weight that necessitated humane sacrifice. All subsequent antitumoral studies used a standard dosing regimen of five daily doses of 20 mg/kg body weight. The response of small, palpable HepG2 and HNX 14C tumors not expressing NTR to this CB1954 dosing regime was also investigated. As shown in Figure 4 , CB1954 administration had no discernible effect on the growth rate of either parental tumor type. Figure 5 shows the effects on tumor growth rate and host animal survival of administering CB1954 to mice bearing small tumors (6 -20 mm 2 ) formed from the NTR-expressing cell lines. For both tumor types, a substantial inhibition of the average growth rate was observed, and the majority of mice had no macroscopically detectable tumor at the conclusion of the experiment (Table 1) . No spontaneous remissions were observed among tumor-bearing animals not treated with prodrug. More careful examination of longterm-surviving tumor-free mice using cytohistology revealed no evidence of tumors in the fibrotic scars remaining at the tumor site.
Regression of large tumors expressing NTR Because larger tumors are usually more difficult to treat with chemotherapy, the effect of the CB1954 system on larger NTR-expressing xenografts (65-85 mm 2 ) was evaluated. As shown in Figure 6 , the treatment caused a rapid reduction in average tumor size for both tumor types. Regression was particularly striking for the HepG2/ntr 7 tumors, for which a 50% reduction was observed during the 5-day period of prodrug administration (Fig 6, B1) . As with smaller tumors, some of the treated animals showed complete regression with no reappearance of tumors in the long term. However, fewer animals were cured (Table 1) . Nevertheless, CB1954 treatment gave a substantial improvement in 
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time to compulsory sacrifice compared with administration of vehicle only, as shown in Figure 6 , A2 and B2.
Histopathological changes in NTR-expressing HepG2 xenografts induced by CB1954
Next, studies were conducted to characterize the histopathological changes associated with the antitumoral effects of the ntr/CB1954 system. Nude mice bearing palpable HepG2/ntr 7 tumors were treated with CB1954 and sacrificed at the following timepoints: 12 hours, 24 hours, 48 hours, 72 hours, and 96 hours after the first injection of the prodrug. Tumors were excised at each timepoint, and sections were analyzed by H&E staining and immunostaining with the anti-NTR antiserum (Fig  7) . H&E staining revealed a large number of apoptotic cells, characterized by condensed and fragmented nuclei, adjacent to blood microvessels (Fig 7, A1) ; these apoptotic cells were evident even at the 12-hour timepoint. Consistent with induction of apoptosis by activated CB1954, adjacent sections contained abundant NTR-expressing cells (Fig 7, A2) . Apoptosis became more widespread over the next 36 hours, as did secondary necrosis and disruption of the microvasculature, resulting in coagulative necrosis in the center of the tumor (Fig 7C) . However, viable tumor cells were detectable in the peripheral zone of the tumor. Xenografts excised after 72 hours exhibited evidence of mononuclear cell infiltration (Fig 7D) . At the 96-hour timepoint, distinct vacuoles were observed and residual tumor was replaced by fibrous tissue (Fig 7, E1 and E2 ).
No signs of toxicity in the subcutis adjacent to the tumor xenograft were observed. Dependence of antitumoral effects upon the proportion of tumor cells expressing NTR To determine the magnitude of the bystander effect of the ntr/CB1954 system in established tumors, mice were inoculated with mixtures of HepG2 and HepG2/ntr 7 cells containing 0%, 1%, 5%, 20%, or 100% HepG2/ntr 7 cells. Anti-NTR immunostaining of sections of these chimeric tumors showed that these proportions of NTRexpressing cells were maintained during growth of the tumors (data not shown). These data show that CB1954 treatment caused a significant reduction in the growth rate of tumors containing only 5% of cells expressing NTR (Fig 8) . More strikingly, the survival of some animals was greatly extended, showing that the ntr/ CB1954 system results in pronounced bystander cell killing in vivo.
In experiments more closely resembling the clinical situation, the bystander effect of the ntr/CB1954 system was investigated after injection of parental HepG2 tumors with an ntr expression plasmid (pTX0340). Immunostaining of sections of injected tumors with the anti-NTR antibody showed maximal NTR expression at 24 hours after plasmid injection (data not shown). At this timepoint, ϳ0.1% of cells in the tumor were found to express NTR.
Tumors ϳ40 mm 2 in size were then injected with pTX0340, with the control plasmid pCMV-LacZ, or with saline vehicle only. Animals were treated with CB1954 or vehicle after 24 hours, and tumor growth and animal survival were recorded (Fig 9) . The growth of tumors injected with the LacZ plasmid or vehicle was unaffected by CB1954 treatment. In contrast, injection of the NTR expression plasmid followed by CB1954 treatment led to a significant effect on tumor growth rate and time to compulsory sacrifice. This effect was reproduced in a repeat experiment (data not shown).
DISCUSSION
The GDEPT approach to cancer appears to be very promising, but it is likely that enzyme/prodrug combinations superior to tk/GCV and cd/5-fluorocytosine will be required to obtain good antitumoral effects in the clinical situation. Combinations generating drugs that kill nonproliferating cells as well as proliferating cancer cells and that mediate potent killing of bystander tumor cells by virtue of diffusibility and cell permeability would be preferable. Activation of oxazaphosphorine drugs by tumor cells engineered to express cytochrome p450 enzymes is representative of this second category of GDEPT system. 6 -8 Although effective, a drawback of this approach is that endogenous p450 enzymes will mediate extratumoral prodrug activation, reducing the targeting effect. The combination of 4-([2-chloroethyl][2-mesyloxyethyl]amino)benzoyl-L-glutamic acid (a glutamic acid prodrug derivative of a benzoic acid mustard) and bacterial carboxypeptidase G2 9 avoids this problem because there is no functionally equivalent endogenous enzyme in humans capable of activating the prodrug efficiently. The prodrug CB1954, which is similarly inert, 19 has been shown to mediate potent in vitro tumor cell killing of cells engineered to express E. coli NTR as well as cocultured nonexpressing tumor cells. 11, 20 In this study, we investigated the in vivo efficacy of the ntr/CB1954 system using xenograft models of hepatocellular carcinoma and squamous carcinoma of the head and neck. These tumor types were selected because they will be two of the earliest clinical targets for the system, as they are amenable to targeting ntr gene delivery by direct i.t. injection, which will allow use of the powerful, ubiquitous CMV promoter to drive high-level NTR expression.
Most of the work reported here used human tumor cell lines engineered to express NTR in a constitutive fashion. Our initial in vitro experiments confirmed that NTR expression sensitized both HepG2 and HNX 14C cells to killing by CB1954 (i.e., with optimum exposure to the prodrug). The HepG2/ntr 7 cell line proved more susceptible to killing by CB1954 than the HNX 14C/ntr 8 line under these conditions. However, it is not clear whether this reflects differences in the level of NTR expression or a different inherent sensitivity of the two cell types to the treatment. Significantly, the concentration of CB1954 required to induce 50% cell killing for the less sensitive HNX 14C line, as determined by clonogenic assay, was lower than that achievable in vivo (our unpublished pharmacokinetic data).
Our studies with NTR-expressing tumors derived from the HepG2/ntr 7 and HNX 14C/ntr 8 cell lines clearly demonstrate the in vivo antitumoral efficacy and selectivity of the ntr/CB1954 system. For both tumor types, complete regressions and long-term cures were achieved by systemic administration of CB1954, even when these tumors were very large at the commencement of prodrug treatment. Large HepG2 tumors in particular showed a very rapid reduction in size, detectable in some cases after only the first of the five daily prodrug doses. This may reflect the greater sensitivity of the HepG2/ntr 7 cell line to the prodrug and/or the more extensive vascularization of HepG2 tumors. The basis for tumor relapse, which was most frequently observed with larger tumors, is not yet clear. However, this is most likely due to instability of NTR expression in vivo rather than to resistance to the treatment, as tumors that regrew after initial regression were shown to contain largely (Ͼ90%) NTR-negative cells.
The antitumoral effects we observed were completely dependent upon prodrug activation by NTR, as tumors derived from nonexpressing parental cells were totally unaffected by prodrug treatment. Consistent with this finding, regression of NTR-expressing tumors was not accompanied by any detectable adverse events, except minor transient weight loss, which we also observed after administration of the prodrug to mice bearing no tumors. Histological examination revealed no significant deleterious effects on normal tissues in the vicinity of the tumors during or after tumor regression. Such examination also revealed that only fibrous tissue remained at the site of tumors after complete regression, with no sign of residual tumor cells. The results therefore suggest that the ntr/ CB1954 system is capable of selective and complete ablation of tumor cells.
The results of histological examination during tumor regression were consistent with previous reports 12, 13 that the ntr/CB1954 system kills cells through induction of apoptosis. Our results also showed, however, that apoptotic cell death was followed by necrosis at later timepoints, suggesting that the macrophage infiltration 2 ) were injected three times with the NTR expression vector pTX0340 on day Ϫ1 as described in Materials and Methods. CB1954 or vehicle treatment was started 24 hours later and continued for 5 consecutive days. Control groups of tumors were injected with saline or pCMV-LacZ or left uninjected before being treated with CB1954 or vehicle (20% DMSO/saline; 15 mL/kg) as described above. Each group contained five mice. Data are presented (a) as average tumor size Ϯ SEM versus time and (b) as the percentage of surviving mice (tumors Ͻ100 mm 2 ) versus time. Survival curves were obtained by recording the total survival days for each mouse in different groups from the day of injection of CB1954 (day 0, 100% survival) to the day of sacrifice.
observed was insufficient to remove all cells killed by activated prodrug. This may simply be because the animals were immunodeficient.
The present generation of gene delivery vectors will not result in delivery to all cells in tumors. To achieve clinical benefit, it will therefore be essential that the enzyme/prodrug system generate an active drug that allows killing of bystander tumor cells. Such bystander killing has been demonstrated for the tk/GCV system, although it is most likely mediated through transmission of secondary apoptosis promoters via connexinrelated cell contact rather than through a diffusible and active metabolite of the prodrug. 21 Bystander effects are usually not detectable for the tk/GCV system in immunocompromised mice, which has led to the view that immune effects are required. 4 Bystander effects have been reported for the ntr/CB1954 system in vitro 14 -16 and have been demonstrated to be mediated by a diffusible metabolite of CB1954. 20 In the present study we clearly demonstrate that antitumoral effects can be achieved in response to CB1954 administration when only a minority of tumor cells express NTR. The experiments with s.c. HepG2 tumors formed from mixtures of cells either expressing or not expressing NTR show that significant antitumoral effects and an improvement in time to compulsory sacrifice result when only 5% of the tumor cells express the enzyme. In agreement with this observation, a similar antitumoral effect was observed when 100% NTR-expressing tumors that relapsed after CB1954 treatment were exposed to a second round of prodrug treatment. These relapsed tumors typically contained up to 10% NTR-expressing cells (our unpublished data). No significant antitumoral effects were observed when only 1% of the tumor cells expressed NTR. Given these data, it is superficially surprising that significant antitumoral effects were observed upon prodrug administration to mice with ϳ0.1% of cells expressing NTR as a consequence of injecting the tumors with an ntr expression plasmid. The most likely explanation for this apparent discrepancy is that injection of the expression plasmid results in much higher expression of NTR per cell than is the case for HepG2/ntr 7, which was originally selected largely for stability of expression. Immunostaining of tumor sections, although not very quantitative, gave results consistent with this explanation.
In summary, we have shown that the ntr/CB1954 system is capable of inducing very potent, long-lasting antitumoral effects with a good therapeutic ratio in established and clinically relevant tumors in mice. We have also used a protocol that mimics the clinical situation, with ntr gene delivery in situ to tumors in mice, to demonstrate that this enzyme/prodrug combination results in potent killing of bystander tumor cells. We are now testing the system using adenovirus as the ntr gene delivery vehicle, because this results in much more efficient gene delivery than naked plasmid DNA.
